

Special Issue

Emerging Therapeutic Approaches to Head and Neck Cancer

Message from the Guest Editors

Head and neck cancers comprise a heterogeneous group of tumors with diverse genetic and molecular profiles. Despite new biological insights, the global survival rate for head and neck cancers has remained unchanged over 30 years, at just over 50% at 5 years. Recently, the KEYNOTE-689 and the NIVOPOST-OP trial represented a significant step forward, exploring the potential use of immune checkpoint inhibitors in locally advanced disease to improve long-term outcomes.

In the recurrent/metastatic setting, immune checkpoint inhibitors are currently being employed, but only a minority of patients derive benefits, underscoring the need for improved patient selection and novel therapeutic strategies.

For this Special Issue, we invite original research, reviews, and clinical trial data focused on the biology of head and neck cancer subtypes and innovative treatment strategies aimed at improving outcomes.

Guest Editors

Prof. Dr. Laura D. Locati

1. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
2. Medical Oncology Unit, Istituti Clinici Scientifici Maugeri-IRCCS SpA SB, Pavia, Italy

Dr. Daria Maria Filippini

Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi, 40138 Bologna, Italy

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/243814

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).